Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Takeda Pharmaceutical (TKPHF) EBIT Margin (2017 - 2025)

Historic EBIT Margin for Takeda Pharmaceutical (TKPHF) over the last 9 years, with Q4 2025 value amounting to 14.17%.

  • Takeda Pharmaceutical's EBIT Margin fell 38300.0% to 14.17% in Q4 2025 from the same period last year, while for Dec 2025 it was 26.74%, marking a year-over-year increase of 69500.0%. This contributed to the annual value of 7.48% for FY2025, which is 24600.0% up from last year.
  • As of Q4 2025, Takeda Pharmaceutical's EBIT Margin stood at 14.17%, which was down 38300.0% from 28.52% recorded in Q3 2025.
  • Takeda Pharmaceutical's EBIT Margin's 5-year high stood at 31.65% during Q1 2025, with a 5-year trough of 0.96% in Q1 2024.
  • Over the past 5 years, Takeda Pharmaceutical's median EBIT Margin value was 16.96% (recorded in 2023), while the average stood at 19.06%.
  • As far as peak fluctuations go, Takeda Pharmaceutical's EBIT Margin tumbled by -168800bps in 2024, and later skyrocketed by 326100bps in 2025.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's EBIT Margin stood at 12.92% in 2021, then grew by 4bps to 13.4% in 2022, then surged by 66bps to 22.24% in 2023, then dropped by -19bps to 18.0% in 2024, then decreased by -21bps to 14.17% in 2025.
  • Its EBIT Margin was 14.17% in Q4 2025, compared to 28.52% in Q3 2025 and 28.72% in Q2 2025.